/
HSCS
$2.75-$0.19 (-6.46%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$9.7M
3M shares
52-week range
$1.63 – $6.47
23% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
297.86%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-167.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|
| Revenue | $64.2K | $25.6K | $14.4K | $5.2K | $18.6K | $4.3K | $89.5M |
| Cost of revenue | $110.3K | $44.3K | $34.5K | $29.7K | $101.2K | $129.8K | $60.5M |
| Gross profit | −$46.1K | −$18.7K | −$20.1K | −$24.6K | −$82.6K | −$125.5K | $29.0M |
| Gross margin | -71.8% | -72.9% | -139.7% | -476.9% | -444.2% | -2884.7% | 32.5% |
| R&D | $2.0M | $1.7M | $3.0M | $2.5M | $2.9M | $4.4M | $0 |
| Operating income | −$3.8M | −$2.6M | −$4.7M | −$6.1M | −$6.3M | −$8.4M | −$16.4M |
| EBITDA | −$3.7M | −$2.3M | −$4.4M | −$6.1M | −$6.2M | −$8.1M | $16.2M |
| Net income | −$3.8M | −$2.5M | −$4.8M | −$6.4M | −$6.6M | −$8.8M | −$12.7M |
| Net margin | -5938.0% | -9577.3% | -33592.6% | -123384.3% | -35511.9% | -201499.5% | -14.2% |
| EPS (diluted) | -115.69 | -77.89 | -145.48 | -79.92 | -18.74 | -9.34 | 0.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $350000 | $-3.02 | $-4.28–$-1.75 | 1 |
| 2028 | $3M | $-2.21 | $-3.14–$-1.28 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
HeartSciences Inc. Common Stock
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
www.heartsciences.com- Employees
- 12
- IPO / List date
- Jun 15, 2022
- HQ
- SOUTHLAKE, TX
Held by traders on TradeandTell
No one on the platform currently holds HSCS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HSCS as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-05-17 | 1-for-100reverse |
Recent trades on TradeandTell
No one on the platform has traded HSCS yet.
